Company reports Quarterly reportsAnnual reports PresentationsAnnouncementsAnnual General MeetingFinancial calendarCorporate governanceData of sharesConferences, roadshowsAnalystsContact Latest reports Richter Group Report - 9 months to September 2020717 kb 11/06/2020let lt sRichter Group Report - 6 months to June 2020619 kb 08/03/2020let lt sRichter Group Report - 3 months to March 2020580 kb 05/08/2020let lt s Latest announcements Extraordinary Announcement01/18/21European Commission decision adopts CHMP opinion on restricting the use of Esmya®01/15/21Gedeon Richter Plc. ("Richter") announces that the European Commission (EC) implemented a decision concerning the marketing authorisations of ulipristal acetate 5 mg (Esmya®) as a result of cases of serious liver injury. This decision follows the opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on 13 November 2020 and is applicable for all Member States in the European Economic Area.Extraordinary Announcement01/12/21
Latest reports Richter Group Report - 9 months to September 2020717 kb 11/06/2020let lt sRichter Group Report - 6 months to June 2020619 kb 08/03/2020let lt sRichter Group Report - 3 months to March 2020580 kb 05/08/2020let lt s
European Commission decision adopts CHMP opinion on restricting the use of Esmya®01/15/21Gedeon Richter Plc. ("Richter") announces that the European Commission (EC) implemented a decision concerning the marketing authorisations of ulipristal acetate 5 mg (Esmya®) as a result of cases of serious liver injury. This decision follows the opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on 13 November 2020 and is applicable for all Member States in the European Economic Area.
